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ABSTRACT 
Novel drug delivery system mainly consents about achieving the targeted concentration to release the drug at targeted site by using carrier 
system, altering the structure and microenvironment around the drug. Especially drugs which are having narrow therapeutic window are 
difficult to formulate, with the advantage of novel drug delivery systems like particulate, polymeric carrier, macromolecular and cellular carriers. 
They are used to reduce complications as well as release the drug in a determined fusion at targeted site. In vesicular drug delivery system drug 
binds covalently to the lipid molecule by which the drug release is in a controlled manner and also drugs which are of hydrophilic or lipophilic 
nature can be delivered by using vesicular drug delivery systems. The release of drug from the vesicles depends on the physicochemical 
properties of both the drug and carrier. Vesicular drug delivery includes liposomes, niososmes, transferosomes, pharmacosomes, electrosomes, 
ethosomes etc. Of all these drug delivery systems pharmacosomes are having more advantages like no leakage or loss of drug, stability, high 
entrapment efficiency etc, pharmacosomes may be hexagonal aggregates , ultrafine vesicular and micellar forms. Both synthetic and natural 
drugs which are facing difficulties like low solubility and low permeability can be effectively formulated and can achieve required 
pharmacokinetic and pharmacodynamic parameters. Pharmacosomes are prepared by hand shaking method, ether injection, solvent 
evaporation method, anhydrous co-solvent lyophilyzation, supercritical fluid approach and other alternative methods they are characterized by 
complex determination, surface morphology, drug entrapment, solubility, drug lipid compatibility, crystal state measurement, dissolution studies 
and in vitro drug release rate.  
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INTRODUCTION  
Novel drug delivery system (NDDS) primarily focuses on 
formulation, technologies, and systems for transporting a 
pharmaceutical compound in the body as needed to safely 
achieve its desired therapeutic effects. Safely novel drug 
delivery is far better than the conventional dosage form. 
Novel drug delivery system should full fill the following 
requirements: 
 Firstly, it delivers specific amount of drug at a rate 
directed by the needs of the body, over the period of 
treatment. 
 Secondly, it delivers the active drug moiety to the 
targeted site of action.1 
Advantages of novel drug delivery systems  
 Optimal dose at the right time and right location  
 Efficient use of expensive drugs and excipients 
 Cost efficient and also show more benefits than other 
novel drug delivery systems. 
 Better therapy and improved comfort  and standard of 
living  
 The adverse effects and also toxic effects are minimized 
Basic modes of novel drug delivery system are:   
1. Targeted drug delivery system. 
2. Controlled drug delivery system. 
3. Modulated drug delivery system.  
Vesicular drug delivery systems  
Nowadays vesicular drug delivery is one of the advanced 
novel drug delivery system. Biological origins of the vesicles 
were first reported by the Bingham in year of 1965, so they 
termed as “Bingham bodies”. 2   
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From the past few years, vesicles have evolved by the vehicle 
of choice in novel drug delivery. Vesicular drug delivery has 
immense worth in genetic engineering, immunological, 
membrane, biological and diagnostic techniques. Vesicular 
drug delivery plays a vital role in modeling membrane as 
well as in the targeting and delivery of active principle. 3 
Drug carriers are the substance which used in the process of 
drug delivery and they help to improve the drug 
effectiveness, selectivity, and/or safety in administration of 
drug.  
Drug carriers release the drug in systemic circulation in a 
controlled manner. This can be attained either by slow 
release of drug over a long period of time or by actuated 
release at the drug target by some stimulants such as 
changes in pH, application of heat, and activation by light. 
Especially, in the case of drugs with poor water solubility 
and/or membrane permeability, drug carriers are used to 
improve their pharmacokinetic and the bioavailability. 4 
Liposomes consist of either natural or synthetic 
phospholipids. 5 They consist of hydrophilic, lipophilic and 
amphiphilic moieties which help in accommodation of the 
drug molecule having a wide array of solubility. These 
vesicles are variable and controllable and their properties 
can be supervised by modifying the vesicle structure, size, 
lamellarity, tapped density, surface charge and 
concentration. It can be a depository and release drug in a 
controlled way. 6 
The pharmaceutical carriers are classified as particulate 
type, polymeric, macromolecular and cellular carriers. 
Particulate types of carriers are also known as colloidal 
carriers which include lipid particles of low and high density 
lipoproteins, low density lipoproteins and high density 
lipoproteins. 7 A wide variety of drug carriers are being 
studied and each of them has unique benefits and ill effects. 
More prominent type of drug carriers are niosomes, 
liposomes, polymeric micelles, microspheres, and 
nanoparticles. The different methods present in binding the 
drug with carrier include adsorption, encapsulation and 
covalent bonding. Different type drug carriers utilize 
different type of attachment methods. 4 
 
 
Figure 1: Pharmaceutical carriers of pharmacosomes 
 
Advantages of vesicular drug delivery system  
 They extend the presence of the drug in systemic 
circulation. 
 Vesicular drug delivery is an efficacious method for 
reducing the drug toxicity and targeting to the site of 
action.  
 This system improves the bioavailability principally in 
case of the poorly aqueous soluble drugs. 
 In this systems both the hydrophilic and lipophilic drugs 
are embodied.  
 It sustains the release of drugs by delaying the time of 
elimination through they are rapidly metabolizable. 8 
 They overcoming the problems regarding stability, 
solubility and degradation of the drug.  
 The limitations of conventional dosage forms can be 
triumph by acting as drug reservoir by encapsulating 
the drug. 
 The carriers of the vesicular drug delivery system are 
biocompatible and biodegradable as they are similar to 
biomolecular functions and structure.  
 Vesicular systems are associated with some 
complications of drug carrier such as particulates and 
loading of drug passively, which may lead to decrease in 
drug loading efficiency and leakage of drug during  
formulation, storage and delivery in vivo .9 
Pharmacosomes: 
Pharmacosomes are part of the novel drug delivery system. 
They were first introduced by vaizoglu and Speriser in 1968. 
10 Pharmacosomes are determined as the colloidal 
dispersions, drugs covalently bound to the lipids, and may 
exists as ultra fine vesicular, micellar, or hexagonal 
aggregates,  on the basis of the chemical structure of the 
drug-lipid complex. [10, 11] The system is composed by linking 
a drug (pharmakon) to a carrier (soma), so they termed as 
“Pharmacosomes”. 
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Figure 2: Pharmacosomes  
 Pharmacosomes assist in drug targeting and controlled 
release of drug to achieve desired dose. 
 They bearing unique advantage over liposome and 
niosome vesicles and are serve as an altering to 
conventional vesicles.  
 Problems like drug incorporation, leakage, or 
insufficient shelf life of drug can be avoided in 
pharmacosomes. 
 The concept of creation of the vesicular pharmacosomes 
is in accordance with bulk interaction and surface of 
lipids with drug substances. 
 Drugs occupying an active hydrogen atom (-COOH, -OH, 
-NH2, etc.) can be esterified into the lipid form, with or 
without spacer chain that results in formation of an 
amphiphilic compounds, which helps in the permeation 
into the target site. 
 The prodrug amalgamates have both hydrophilic and 
lipophilic properties, so they acquire amphiphilic nature 
and therefore found to decrease the interfacial tension, 
and mesomorphic behavior at elevated concentrations. 
7,11 
 
 
 
                                  
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Components of pharmacosomes 
 
Advantages of pharmacosomes: 
 When compared with other categories of lipid based 
delivery systems, pharmacosomes exhibit better results 
in many ways. 
 The drug-lipid complex depends upon the phase 
transition temperature but independent on rate of 
release as it is covalently bounded to the lipid. 
 No leaching will occur as drug is bounded to the lipid by 
covalent bonding. 
 Delivers drug at the specific site and site targeted. 
 By enzymatic methods like hydrolysis drug is released 
from the lipid polymer. 
 The metabolism of the drug depends on the spacer, 
length of chain in lipid, functional groups and size of the 
drug during its absorption. 
 They reduce the cost of therapy. 
 They are suitable for the both lipophilic and hydrophilic 
drugs. 
 The aqueous solution of the amphiphiles exhibits 
concentration dependant aggregation. 
 The drug and carrier are covalently linked together so, 
entrapment efficiency is high and predetermined. 
 Drug release of pharmacosomes is by hydrolysis. 
 They improves the bioavailability majorly incase of 
poorly soluble drugs. 
 They reduce the adverse effects and toxicity. 
 In pharmacosomes, there is no need to remove the 
unentrapped drug when compared to liposomes where 
the free drug should be removed 
 Drugs like bupranolol hydrochloride, pindolol maleate, 
acyclovir, taxol, etc by using of pharmacosomes drug 
delivery has therapeutic performance has been 
improved.9,10 
Hexagonal aggregates Ultrafine vesicular Miscellar 
Pharmacosomes 
Lipid components 
Phosphotidylecholine Phosphotidylinosital 
Diphosphotidylglycerol (cardiopin) Phosphotidyletiolamine 
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Disadvantages of pharmacosomes: 
 Water insoluble drugs are encapsulated relatively in a 
less hydrophobic region within membrane bilayer 
rather than relatively large surface area. 
 The storage of pharmacosomes undergoes fusion and 
aggregation as well as chemical hydrolysis.12 
Salient features of pharmacosomes: 
 Pharmacosomes can be administered in various route 
such as orally, extra vascular and intravascular. 
 The drug conjugates with lipids and results in high 
entrapment efficacy in predetermined fashion. 
 There is no problem when the drug is incorporated into 
the lipid. 
 They consist of both hydrophilic and lipophilic 
properties so they can easily pass through the cell 
membrane, walls, or tissues either by action of 
endocytosis or exocytosis. 
 The physicochemical characters of the drug-lipid 
complex affect the stability of pharmacosomes. 
Limitations of pharmacosomes: 
 Amphiphilicity is required in the compound. 
 Both the surface and bulk interaction may be observed. 
 Drug should be covalently bounded to the lipid. 
Components of pharmacosomes:  
The components for pharmacosomes preparation are: Drug, 
Solvent and Lipid. 
Drugs  
 Any drug containing active hydrogen atom (-COOH, -OH, -
NH2, etc) can be esterified with the lipid, with or without 
spacer chain. Facilitates membrane, tissue, cell wall transfer 
in the organisms is due to its amphiphilic nature. 
Solvents  
They should be high pure and volatile in nature, and should 
be selected based on the intermediate polarity for their 
preparations. 
Lipids  
 Phospholipids are the major components of biological 
membrane; majorly two types of phospholipids are used 
namely phosphoglycerides and sphingolipids.  
 The most common type of phospholipids is 
Phosphotidylecholine moiety. 
 Phosphotidylecholine is an amphiphilic molecule in 
which a glycerol bridges links a pair of hydrophobic 
acylhydrocarbon chains with hydrophilic polar head 
group phosphocholine.13 
Applications of phosphotidylecholine  
 Phosphotidylecholine place a vital role in supporting 
cell membrane integrity and basic biological process. 
 Impairment of cell membrane and its repair which 
results in liver disorders can be managed and also acts 
as a hepato-protective agent by acting as supplement 
source of choline. 
 It can also promote breakdown of collagen and prevent 
fibrosis and cirrhosis. 
 It also shows protection against hepatitis A, B & C. 
 It can acts as supplement in treatment of Alzheimer’s 
disease. 
 It also have therapeutic role in cancer patients. 
 It shows reduction of serum cholesterol level by which 
it can shows as anti-hyper lipidimic. 
Preparation of pharmacosomes: 
There are two methods which have been employed to 
prepare pharmacosomes; 
1) Hand-shaking method 
 In the hand-shaking method, both the drug and lipid 
shell be mixed in the round bottomed flask. 
 The organic solvent is evaporated by using rotary 
vaccum evaporator at room temperature, results in 
formation of a thin film of deposition on the walls. 
 The dried film is then hydrated with buffer and rotated 
in one direction with hand which results in the 
formation of  vesicular suspension.[13] 
2) Ether injection method   
 The drug-lipid complex is dissolved in specified 
volume of ether. 
 Then the above mixture is slowly injected into a heated 
buffer solution, resulting in the formation of the 
vesicles. 
 The nature of vesicle especially the shape depends on 
the concentration. 
 The variety of structures may be formed that are, 
round, cylindrical, disc, cubic, or hexagonal type 
depending on the amphiphilic state.9,14,15 
3) Anhydrous co-solvent lyophilyzation method 
 Drug and phospholipids are dissolved in solution of 
dimethyle sulfoxide containing glacial acetic acid. 
 Then the above mixture is agitated to get clear liquid 
and then freeze-dried overnight at condenser 
temperature. 
 The complex obtained is flushed with nitrogen and 
stored at 4˚c.16 
        4) Supercritical fluid process   
 This method is known as solution enhanced dispersion 
by complex supercritical fluid. Drug and lipid complex 
are premixed in a supercritical fluid of carbon dioxide, 
then high super saturation is obtained by passing 
through the nozzle mixture chamber. 
 The turbulent flow of solvent and carbon dioxide results 
in fast mixing of dispersion leading to the formation of 
pharmacosomes. 
        5) Solvent evaporation method 
 In the solvent evaporation method of preparing the 
pharmacosomes, the drug is first acidified so that the 
active hydrogen might be available for complexation. 
  The drug acid is then extracted into chloroform and 
subsequently recrystallized. The drug-PC complex is 
prepared by associating drug acid with PC in various 
molar ratios. 
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 The accurately weighed PC and drug acid are placed in a 
100 ml round bottom flask and dissolved in sufficient 
amount of dichloromethane.  
 The mixture is refluxed for one hour. Then the solvent is 
evaporated off under vacuum at 40 ° C in a rotary 
vacuum evaporator. 
 The dried residues are then collected and placed in 
vacuum desiccator for complete drying. 
6) Recent approaches  
 A biodegradable micelle forming drug conjugate was 
synthesized from the polymer consisting of 
polyxyethylene glycol and polyaspartic acid with a 
Adriamycin which is hydrophobic in nature. 
 Diluting the micelle without the active constituent 
getting precipitated in the monomeric drug conjugate. 13 
 Diluting lyotropic liquid crystals of amphiphilic drug by 
Muller-Goymann and Hamann.17 
 Phosphotidylethanolamine with various molar ratios of 
Phosphotidylecholine and cholesterol which 
significantly enhanced cytoprotection by encapsulating 
amoxicilin Singh et al. formulated “vesicular 
constructs”using aqueous domain.18 
Characterization of pharmacosomes 
1) Complex determination 
Using correlation spectrum the formation of both conjugate 
and complex can be contingent upon inspecting with that of 
discrete constituents and also with their mixture using FTIR 
spectrum. 19 
2) Surface morphology 
The surface morphology can be predicted using Scanning 
Electron Microscopy (SEM) or Transmission Electron 
Microscopy (TEM). The shape and size of pharmacosomes 
are prone to variations by some variables such as rotation 
speed, vaccum applied, Purity grade of phospholipids or the 
method used. 
3) Drug entrapment  
To know the amount of drug present in the drug complex 
estimated quantity of pharmacosomes were transferred into 
a suitable flask containing known volume of solvent in which 
drug is soluble. Mix the above contents thoroughly or 
sonicate, leave the contents for 24 hrs without disturbing 
and estimate the dug present by using UV spectroscopy or 
HPLC. 
4) Solubility    
Solubility is determined by placing the known amount of 
phospholipid complex in a screw caped penicillin bottle 
containing aqueous phase buffer solution of varying pH (2-
7.4) and organic phase like 1- Octonol with continuous 
shaking at a temperature of 37οc for 24hrs. Then both the 
layers will be separated and samples were analyzed using 
HPLC or UV spectrophotometer 20 
5) Drug lipid compatibility 
Differential scanning electron microscopy is a thermo 
analytical technique used to determine drug-lipid 
compatibility and their interactions. Thermal response is 
studied by using separate sample and heating them in a 
sample pan, which is closed. The nitrogen gas is plugged, and 
the temperature is maintained in a definite range with a 
specific heating rate. 
6) Crystal state measurement  
The crystal nature of the drug can be determined by using X-
ray diffraction technique. The tube voltage and tube current 
can be regulated in the X-ray generator. Copper lines may be 
used as the source of radiations. The overall integrated 
intensity of all reflection peaks are projected by area under 
curve of X-ray diffraction pattern that specifies the specimen 
characteristics. 21  
7) Dissolution studies 
Dissolution studies in vitro are done by using various models 
available using different buffers, then the results obtained 
are estimated on the basis of activity of the drug. 22 
8) In vitro drug release rate 
The in vitro drug release rate is estimated by reverse dialysis 
bag technique. In this method pharmacosomes are 
introduced inside the dialysis bag and the receiver phase is 
placed outside. Dialysis bag containing the continuous phase 
and they are suspended in a vessel containing the donor 
phase and stirred at predetermined time intervals, each 
dialysis bag is removed and the contents are analyzed for 
drug release. An advantage of this technique is increase in 
the membrane surface area available for transport from the 
donor to receptor compartment. Another advantage of this 
technique is the increased efficiency in terms of staffing as a 
consequence of reduction in number of steps. 21 
Applications of pharmacosomes 
 Pharmacosomes possess better stability and shelf life 
compared to other vesicular drug delivery systems. 
 Absorption and permeation of the drug can be enhanced 
formulating in to pharmacosomes. 
 The transportation of drug across the biological 
membranes is due to the vesicular formation as they 
have the capacity to interact with the membranes, due 
to their transitions from vesicle to micelle by altering 
the transition temperature  
 By altering the temperature at the targeting site 
pharmacosomes have the capacity to deliver the drug in 
the targeted site especially in the case of cell specific 
drug vehicles. 
  Pindolol diglyceride, Amoxicillin, Taxol, Cytrabine, 
Dermatansulfate, Bupranolol hydrochloride etc showed 
increase in pharmacological action by formulating into 
pharmacosomes.  
 The mechanism of action of drugs and non bilayer 
phases can be studied by using pharmacosomes. 
 PEGylation and biotinyzation are used in current 
research in the production of pharmacosomes. 
 Ophthalmic drug delivery with a modified corneal drug 
transport and release by diluting with tears where the 
drug should be of amphiphilic in nature 
 Phytoconstituents such as flavonoids, glycosides, 
xanthones etc, shows both increase in pharmacokinetic 
and pharmacodynamic actions. 
 The ability of transportation of  biological components 
like proteins and amino acids by using 
pharmacosomes23 
 Optimizing the preparation of 20(S)-protopanaxadiol 
pharmacosomes showed encapsulation efficiency of 
pharmacosomes.25 
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 Pharmacosomes found to increase solubility and 
permeability of drug than conventional dosage forms in 
Diclofenac and Aceclofenac. [21] [24] 
 Pharmacosomes employed to prepare Tetrahydrofuran 
injection method and studied in the in-vitro behavior in 
rats for didanosine, by which they observed that 
pharmacosomes possess prolonged action in both 
targeted site and liver. 26 
 Pharmacosomes formulated using 3, 5-dioctanoyl-5-
fluro-2-deoxyuridine with a central composite design 
resulted in formation of regulated pharmacosomes, 
shows a great targeting efficiency in both in-vitro and 
enhanced drug capacity to pass through blood brain 
barrier. 27 
 The suppression in hemolytic reaction of 
pharmacosomes of acyclovir by noticing the interaction 
of pharmacosomes with erythrocytes and plasma 
proteins after absorption. 28 
 Improved bioavailability and reduced gastrointestinal 
toxicity in aspirin was predicted by preparing aspirin 
phospholipid complex. 29 
CONCLUSION  
In pharmacosomes drug is bound to the polymer by covalent, 
van der Waal and hydrogen bonding. The drug will be 
released will by hydrogen bonding. Pharmacosomes achieve 
desired dose by drug targeting in controlled release. The 
pro-drugs can be amalgamated acquiring amphiphilic in 
nature. Both the lipophilic and hydrophilic drugs can be 
suitable candidates, by covalent bonding with the polymer 
shows increase in entrapment efficiency. Pharmacosomes 
reduce toxicity and can improve therapeutic performance of 
drug. A biodegradable micelle forming drug conjugates 
increasing hydrophilicity of drug, Whereas change in the 
ratio of polymers show enhance cytoprotection by 
formulation of “vesicular constructs “using aqueous domain . 
 
Table 1: Comparing various methods and their outcomes of drugs using pharmacosomes 21, 24, 26, 30-39 
S. 
no 
Drug Polymers Solvents Bonding Technique used  Results Final product 
1 Geniposide Phospholipids Tetrahydrofuran Hydrogen, 
van der 
waal 
forces 
Vaccum 
evaporation 
method 
Lipid 
solubility 
character of 
Geniposide 
was increased 
Dry powdered 
pharmacosomes 
2 Naproxen Soya lecithin Diethyl ether, 
ethanol, acetone 
Covalent 
bond 
Ether injection 
method 
Solubility 
enhanced and 
achieved 
controlled 
drug release 
Pharmacosomes 
gel 
3 Aspirin Soya 
phosphotidylecholine 
Dichloromethane Covalent 
bond 
Solvent 
evaporation 
Improved 
drug delivery 
controlled 
drug delivery 
Pharmacosomes 
4 Aceclofenac Soya 
phosphotidylecholine 
Dichloromethane Covalent 
bond 
Solvent 
evaporation 
Enhancement 
of solubility 
and 
dissolution 
profile and 
improved 
bioavailability  
Pharmacosomes 
5 Furosemide Soya 
phosphotidylecholine 
Methyl alcohol Hydrogen 
bond 
Vaccum 
evaporation 
Release and 
permeation 
increased 
Pharmacosomes 
6 Ketoprofen Soya 
phosphotidylecholine 
Dichloromethane - Solvent 
evaporation 
Improved 
solubility, 
dissolution 
profile 
Pharmacosomes 
7 Etodolac Soya lecithin Acetone, 
dichloromethane, 
methanol 
- Thin film 
hydration 
Increased 
solubility, 
entrapment 
efficiency and 
sustained 
relaese 
Pharmacosomes 
gel 
 
8 
Rosuvastatin Soya lecithin Chloroform, 
dichloromethane 
- Solvent 
evaporation 
Sustained 
drug release 
and improved 
bioavailability   
Pharmacosomes  
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9 
Losartan  Soya lecithin Dichloromethane, 
hydrochloric acid, 
chloroform 
Covalent 
bond 
Solvent 
evaporation 
Increased 
solubility, 
dissolution 
profile and 
bioavailability 
Pharmacosomes  
 
10 
Acyclovir Phosphotidylecholine  - -  
Tetrahydrofuran 
injection method 
Increased 
solubility and 
also hemolytic 
reaction 
Pharmacosomes 
gel 
   
11 
Bupranolol  Soya lecithin  - Covalent 
bond 
- Enhanced 
effect on 
intraocular 
pressure and 
enhance 
lymph 
transport. 
Pharmacosomes  
12 Pindolol  Soya lecithin - - Film and ether 
injection method 
Increased 
bioavailability 
Pharmacosomes  
13 Ibuprofen  Phosphotidylecholine  Dichloromethane, 
chloroform  
- - Increased 
bioavailability 
Pharmacosomes  
14 Didanosine  Soya lecithin  Chloroform, 
acetone, 
methanol 
- Tetrahydrofuran 
injection method 
Increased 
solubility, 
dissolution 
profile and 
bioavailability 
Pharmacosomes  
15 Diclofenac  Phosphotidylecholine  Dichloromethane  Covalent 
bond 
Solvent 
evaporation  
Improved 
solubility and 
drug loading 
Pharmacosomes  
 
Table 2: Comparison of various vesicular drug delivery systems 41-48 
S. 
no 
Type Ingredients Method Advantages Disadvantages 
1 Liposomes Phosphotidylecholine, 
cholesterol, 
sphingolipids, 
steroids, polymeric 
materials. 
 Sonication method 
 French pressure cell 
 Freeze-thawed 
liposomes 
 Lipid film hydration by 
hand shaking or freeze 
drying 
 Suitable for delivery of 
hydrophilic, hydrophobic 
drugs. Biocompatible 
 suitable for controlled drug 
delivery 
 localized action in particular 
tissue 
 High production cost 
 leakage (or) fusion of 
encapsulated drug 
 phospholipid undergo 
hydrolysis  (or) 
oxidation reaction 
 short half life and low 
solubility 
2 Niosomes Surfactants, 
cholesterol, alkyl 
amides, fatty acids 
and amide acid 
compounds 
 Sonication 
 Microfluididation 
 Hand shaking 
 Ether injection 
 Reverse phase 
evaporation 
 Bubble method 
 Active transport 
 
 Stable, increase the stability 
of entrapment drug 
 Improved oral bioavailability 
of poorly absorbed drugs 
 PEG-glucose conjugates on 
the surface of niosomes 
significantly improved tumor 
targeting of an encapsulated 
paramagnetic agent 
 Time consuming 
 In efficient drug loading 
 Requires specialized 
equipments 
3 Pharmacosomes Solvents, 
phospholipids 
 Sonication 
 Hand shaking method 
 Ether injection 
 Anhydrous co-solvent 
lyophilyzation 
 No leaching will occur as 
drug bounded to the lipid by 
covalent bonding 
 Delivers the drug at the site 
specific and site targeted 
 They reduces the cost 
therapy 
 Reduces the adverse effects 
and toxicity 
 The storage of 
pharmacosomes 
undergoes fusion, 
aggregation and 
hydrolysis 
 Water insoluble drugs 
are encapsulated 
relatively in a less 
hydrophobic region 
within membrane 
bilayer or relatively large 
surface are 
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4 Phytosomes Phospholipids, 
commercial products, 
flavonoids 
 
Solvent evaporation 
 Salting out 
lyophilyzation 
 Rotary evaporation 
 Anti solvent 
precipitation 
 As the efficacy increases the 
dosage requirement is also 
reduced 
 They have better stability 
 By increasing solubility of 
bile to herbal origin 
Phytoconstituents 
Phytosomes enhance the 
liver targeting 
 Time period of action is 
increased 
 Duration of action is 
short 
 Phytoconstituents is 
rapidly eliminated from 
Phytosomes 
5 Transferosomes Phospholipids, 
surfactants, alcohols, 
dye, buffering agents 
 
 Thin film hydration 
method 
 Modified hand shaking 
method 
 Vortexing-sonication 
method 
 Suspension 
homogenization process 
Aqueous lipid 
suspension process 
 Centrifugation process 
 High entrapment efficiency 
in case of lipophilic drugs 
 They protect the 
encapsulated drug from 
metabolic degradation 
 They are chemically 
unstable because of  
prediosition to oxidative 
degradation 
 Their formulation and 
manufacturing expensive 
6 Aquasomes Polymers, ceramic 
core 
 Preparation of core 
 Carbohydrate coating 
 Immobilization of drugs 
 Aquasomes preserves the 
conformational integrity and 
biochemical stability of 
bioactive molecules 
 Aquasomes exhibit physical 
properties of colloids 
 Aquasomes avoids 
reticuloendothelial clearance 
or degradation by other 
environmental challenges 
 Aquasomes suspensions 
contain colloidal range 
biodegradable nanoparticles, 
they are more concentrated 
in liver and muscles 
-- 
7 Virosomes Unilamellar 
phospholipid 
membrane, proteins 
 Selection of virus 
 Selection of antigen 
 Reconstituted of 
Virosomes 
 Biodegradable , 
biocompatible and non-toxic 
 No disease transmission risk 
 Applicable for drugs( anti-
cancer, proteins, peptides, 
antibiotics, fungicides) 
 Drug delivery into cytoplasm 
of target cell 
 Noautoimmunogenity or 
anaphylaxis 
 Shorter shelf life 
 Non availability of data 
related to the chronic 
use of virosomal carrier 
system 
 Poor quality of raw 
materials 
 Manufacturing problems 
8 Bilosomes Non-ionic surfactants, 
bile salts, charge 
inducers 
 Hot homogenization 
 Thin film hydration 
 They allow small quantities 
of antigen to be effective and 
also increase efficacy of 
antigen which are weak 
when injected 
 Less toxicity envelop 
suitable for a wide range of 
therapeutic agents 
 They removes cold chain 
requirement for preparation 
such as vaccine 
- 
9 Emulsomes Lipid core, 
antioxidants, 
negatively charged 
particles, surfactants, 
phospholipids, 
cholesterol 
 Lipid film formation 
 Reverse phase 
evaporation 
 High-pressure extrusion 
technique 
 Sonication method 
 Cast film 
 Ethanol  injection 
 Detergent removal 
technique 
 Emulsomes increase the 
solubility and bioavailability 
of poorly aqueous soluble 
drugs 
 Hydrophilic head-group 
facing the water on both 
sides 
 They are composed of lipid 
core, lipids are used to 
develop oral controlled drug 
 They provide significantly 
modify the pharmacokinetics 
of drugs 
- 
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10 Ethosomes Phosphotidylecholine, 
phosphotidic acid, 
phosphotidyle serine, 
cholesterol, alcohol, 
non-ionic surfactants 
 Cold method 
 Hot method 
 It contains non-toxic raw 
materials in formulation 
 Ethosomes drug delivery can 
be applied widely in 
pharmaceutical, veterinary, 
cosmetic field 
 Simple method for drug 
delivery in comparison to 
iontophoresis and 
phonophoresis and other 
complicated method 
 Poor yield 
 If shell looking is 
ineffective then the 
coalescence of 
ethosomes may occur 
and fall apart on transfer 
into water 
 Leakage of product 
during transfer from 
organic to water media 
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